Dennis Cho Sells 806 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total transaction of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The stock was sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00.

Twist Bioscience Trading Up 3.2 %

NASDAQ TWST traded up $1.64 during trading on Wednesday, reaching $53.66. The company’s stock had a trading volume of 942,523 shares, compared to its average volume of 781,392. The firm has a 50 day moving average price of $48.63 and a 200 day moving average price of $46.21. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -14.91 and a beta of 1.87. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.75) EPS. On average, equities analysts forecast that Twist Bioscience Co. will post -2.27 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on TWST. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Barclays reduced their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $53.80.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at approximately $34,000. Van ECK Associates Corp increased its position in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Signaturefd LLC increased its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. US Bancorp DE increased its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $95,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.